Plain-English translation of NCT07606339 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn Disease research guide →This is a real-world study of guselkumab, a medication that helps treat moderate-to-severe Crohn's disease and ulcerative colitis. The study is not giving you the medication—instead, researchers will collect information from your regular doctor visits and medical records to understand how long patients keep taking this treatment and how well it works for them over time.
Doctors want to better understand whether patients stick with this medication in actual clinical practice and what happens to their treatment over months and years. This real-world information is different from what happens in controlled clinical trials, so it helps doctors see how the treatment actually performs in everyday life.
You likely qualify if…
You likely don't qualify if…
You will not receive the medication through this study—your doctor is already prescribing guselkumab to you as part of your regular care. Researchers will simply collect and review information from your medical records and doctor visits to track how long you continue the treatment and how it affects your disease. This is a non-invasive study that works alongside your normal medical appointments.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
Austria
Sponsor
Janssen-Cilag Pharma GmbH
Enrollment target
~35 participants
Started
June 2026
Primary completion
June 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Study Contact
Janssen-Cilag Pharma GmbH
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.